Načítá se...
Temozolamide as an adjuvant in glioblastoma. How long? The experience of a cancer center in Colombia
Introduction: glioblastoma multiforme is considered to be highly lethal, for which the optimal duration of adjuvant temozolamide chemotherapy has not been determined.Objective: to evaluate survival according to the length of adjuvant chemotherapy based on the standard Stupp platform protocol.Mater...
Uloženo v:
| Vydáno v: | Acta Médica Colombiana |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Asociación Colombiana de Medicina Interna
2020
|
| Témata: | |
| On-line přístup: | https://www.redalyc.org/articulo.oa?id=163168638005 https://www.redalyc.org/journal/1631/163168638005/ https://www.redalyc.org/journal/1631/163168638005/html/ https://www.redalyc.org/journal/1631/163168638005/163168638005.epub https://www.redalyc.org/journal/1631/163168638005/movil |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|